[Education] Genitourinary Cancers: Top 10 Clinical Pearls

HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

 

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

 

In this episode of HOPA Now, Dr. Lisa Holle discusses genitourinary cancer clinical pearls, including bladder cancer survival benefit options such as split dose treatments, primary treatment options for early and late-stage renal cancers, bone modifying agent recommendations for patients with bone metastases and management for asymptomatic patients.

 

In this episode you will learn:

 

Genitourinary Cancers: Top 10 Clinical Pearls

• Bladder cancer survival benefit options, including split-dose treatments
• The relationship between vitamin B12 deficiencies and bladder resections
• The primary treatment of early-stage renal cancer with one exception
• Criteria for the treatment of stage 4 renal cancer
• Bone-modifying agent recommendations for renal cancer
• Management for asymptomatic, early-stage prostate cancer patients
• Relugolix as an ADT option in some prostate cancers
• Considerations for treatment of relapsed or refractory prostate cancer patients
• Dosing of bone-modifying agents used in prostate cancer patients
• Radiation therapy recommendations based on cancer stages
• Preferred chemotherapy for nonseminoma and seminoma
• Bleomycin pulmonary toxicity

 

Mentioned in This Episode:

HOPA

 

Quotes:

 

“In early-stage renal cancer, no established role exists for adjuvant therapy except in patients with stage 3 renal cell cancer of clear cell histology and high risk for relapse.” — Dr. Lisa Holle

 

“Bone-modifying agents are recommended for renal cell cancer patients with bone metastases.” — Dr. Lisa Holle

 

“Early-stage prostate cancer patients have a very high rate of 10-year survival.” — Dr. Lisa Holle